These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10214748)

  • 1. Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow?
    Goetz CG; Blasucci L; Stebbins GT
    Neurology; 1999 Apr; 52(6):1227-9. PubMed ID: 10214748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from pergolide to pramipexole in patients with Parkinson's disease.
    Hanna PA; Ratkos L; Ondo WG; Jankovic J
    J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
    JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.
    Wong KS; Lu CS; Shan DE; Yang CC; Tsoi TH; Mok V
    J Neurol Sci; 2003 Dec; 216(1):81-7. PubMed ID: 14607306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke C E; Speller J M; Clarke J A
    Cochrane Database Syst Rev; 2000; 2000(3):CD002259. PubMed ID: 10908539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
    Pinter MM; Pogarell O; Oertel WH
    J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):436-41. PubMed ID: 10201413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ropinirole and pramipexole, the new agonists.
    Hobson DE; Pourcher E; Martin WR
    Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S27-33. PubMed ID: 10451757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease.
    Kujawa K; Leurgans S; Raman R; Blasucci L; Goetz CG
    Arch Neurol; 2000 Oct; 57(10):1461-3. PubMed ID: 11030798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
    J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine agonist monotherapy in Parkinson's disease.
    Clarke CE; Guttman M
    Lancet; 2002 Nov; 360(9347):1767-9. PubMed ID: 12480442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching.
    Takahashi H; Nogawa S; Tachibana H; Kawamura J; Abe T; Ogino Y; Kashihara K; Hamada T; Kowa H;
    J Int Med Res; 2008; 36(1):106-14. PubMed ID: 18230274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan.
    Ohno H; Nakajima M; Fujioka S; Iwamoto K; Kawamura M
    J Clin Neurosci; 2009 Jun; 16(6):790-2. PubMed ID: 19286385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramipexole in patients with early Parkinson's disease.
    Hubble JP; Koller WC; Cutler NR; Sramek JJ; Friedman J; Goetz C; Ranhosky A; Korts D; Elvin A
    Clin Neuropharmacol; 1995 Aug; 18(4):338-47. PubMed ID: 8665547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
    Pinter MM; Rutgers AW; Hebenstreit E
    J Neural Transm (Vienna); 2000; 107(11):1307-23. PubMed ID: 11145006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease.
    Künig G; Pogarell O; Möller JC; Delf M; Oertel WH
    Clin Neuropharmacol; 1999; 22(5):301-5. PubMed ID: 10516884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.